Back to Results
First PageMeta Content
Rare diseases / Alexion Pharmaceuticals / Eculizumab / Paroxysmal nocturnal hemoglobinuria / Hemolytic-uremic syndrome / Myasthenia gravis / Hypophosphatasia / Nephrology / Health / Medicine / Acquired hemolytic anemia


Open Document

File Size: 1,14 MB

Share Result on Facebook

Company

Enobia Pharma Corp. / Orphatec Pharmaceuticals / Taligen Therapeutics / Alexion Pharmaceuticals / EU Alexion Pharmaceuticals / Early 2012 The New England Journal / PNH Alexion Pharmaceuticals / NASDAQ Stock Market / Translational Medicine Group February Alexion / /

Country

Germany / Turkey / Japan / Russia / United States / Brazil / Canada / Australia / /

Event

M&A / FDA Phase / Natural Disaster / /

Facility

Research Pipeline / /

IndustryTerm

insurance role / biotechnology drug candidates / /

MarketIndex

NASDAQ 100 / /

MedicalCondition

hypophosphatasia / severe and ultra-rare diseases / rare diseases / refractory myasthenia gravis / severe and refractory myasthenia gravis / genetic deficiency / ambitious refractory neuromyelitis optica / severe and ultra-rare disorders / molybdenum cofactor deficiency / both disorders / paroxysmal nocturnal hemoglobinuria / progressive kidney disease / blood clots / atypical hemolytic uremic syndrome / extreme fatigue / hemolytic uremic syndrome / myasthenia gravis / significantly pulmonary function / ultra-rare blood disorder / fatal metabolic disorder / disease / severe neuromyelitis optica / stroke / ultra-rare diseases / seizure / pain / ultra-rare and life-threatening disorders / heart attack / diseases / uremic syndrome / metabolic disease / disorders / /

MedicalTreatment

kidney dialysis / enzyme replacement therapy / kidney transplant / innovative therapies / dialysis / /

Organization

American Society of Nephrology / Congress / Complement Foundation / European Medicines Agency / American Society of Hematology / Union for Soliris / European Committee / European Commission / STEC-HUS Drug Administration / FDA / European Union / Myasthenia Gravis Foundation of America / European Hematology Association / /

Person

Stephen P. Squinto / /

Position

active and energetic event security manager / Executive Vice President and Head of R&D / /

Product

Soliris / III Market Soliris® (eculizumab) / TT30 / PNH / /

PublishedMedium

the ASN annual / The New England Journal of Medicine / /

Region

Middle East / Latin America / Eastern Europe / Western Europe / Asia-Pacific / /

Technology

antibodies / biotechnology / dialysis / /

SocialTag